This was associated with an increased expression of HLA-E on CD4+ T cells in MS and was reverted by blocking HLA class I on T cells, suggesting that the cytotoxic function of CD56bright NK cells on their targets is inhibited through binding of HLA-E on T cells to the NK cell inhibitory ligand NKG2A. The gene discussed is HLA-E; the disease is myeloid sarcoma.